Literature DB >> 10506644

Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs.

P Johansen1, L Moon, H Tamber, H P Merkle, B Gander, D Sesardic.   

Abstract

Biodegradable polyester microspheres (MS) have shown potential for single-dose vaccines. This study examined the immunogenicity of diphtheria toxoid (Dtxd) microencapsulated in different types of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) MS prepared by the methods of spray-drying and coacervation. We investigated the influence of polymer type (PLGA 50:50 of low M(w); PLA of high M(w); end-group stearylated PLAs of low M(w)) and co-encapsulated excipients (BSA and/or trehalose) on Dtxd content, in vitro release and immunogenicity in guinea pigs. The co-encapsulated trehalose lowered the Dtxd entrapment efficiency in the spray-dried particles from 75 to 56%, whereas albumin alone had no effect in the spray-drying, but improved the encapsulation in the coacervation process. With the hydrophobic, end-group stearylated PLAs, Dtxd could only be encapsulated in the presence of albumin. Guinea pigs immunised with Dtxd-MS made with the relatively hydrophilic PLGA 50:50 exhibited specific and sustained antibody responses over 40 weeks, comparable to the responses to alum-adjuvanted toxoid. In contrast, undetectable or very low antibody responses were determined after immunisation with MS made with hydrophobic polymers. Surprisingly, large (15-60 microm) and small (1-5 microm) MS gave comparable primary antibody responses. In conclusion, the data presented confirm the feasibility of MS vaccines to induce strong, long-lasting protective antibody responses after a single immunisation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506644     DOI: 10.1016/s0264-410x(99)00191-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

Review 2.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

3.  On technological and immunological benefits of multivalent single-injection microsphere vaccines.

Authors:  Gérard Boehm; Marisa Peyre; Dorothea Sesardic; Rachel J Huskisson; Fatme Mawas; Alexandra Douglas; Dorothy Xing; Hans P Merkle; Bruno Gander; Pål Johansen
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 4.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

Review 5.  PLA micro- and nano-particles.

Authors:  Byung Kook Lee; Yeonhee Yun; Kinam Park
Journal:  Adv Drug Deliv Rev       Date:  2016-06-01       Impact factor: 15.470

Review 6.  Delivery of therapeutic proteins.

Authors:  Dipak S Pisal; Matthew P Kosloski; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

Review 7.  Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases.

Authors:  Chi-Ying Lin; Shih-Jie Lin; Yi-Chen Yang; Der-Yuan Wang; Hwei-Fang Cheng; Ming-Kung Yeh
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 8.  Use of lectin-functionalized particles for oral immunotherapy.

Authors:  Susanne C Diesner; Xue-Yan Wang; Erika Jensen-Jarolim; Eva Untersmayr; Franz Gabor
Journal:  Ther Deliv       Date:  2012-02

Review 9.  Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.

Authors:  Yong Gao; Chanuka Wijewardhana; Jamie F S Mann
Journal:  Front Immunol       Date:  2018-02-28       Impact factor: 7.561

Review 10.  Biodegradable polymers for microencapsulation of drugs.

Authors:  Jae Hyung Park; Mingli Ye; Kinam Park
Journal:  Molecules       Date:  2005-01-31       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.